CHUM turns to artificial intelligence to filter scientific articles related to COVID-19

In collaboration with Get started Montreal-based artificial intelligence company My Intelligent Machines, CHUM makes a tracking solution to filter the amount of scientific information associated with COVID. The goal is to reduce the time spent filtering the approximately 2,000 scientific articles published each week and, most importantly, to establish their quality.

To separate wheat from chaff into the mass of information generated by scientific research, the Center hospitalier de l’Université de Montréal (CHUM) signed a three -year partnership last Thursday with a young Montreal startup in artificial intelligence. : My Intelligent Machines (MIMs).

SCALE AI artificial intelligence supercluster is funding the $ 500,000 project.

“The amount of knowledge is always important, but in a pandemic, there is no knowledge,” said Kathy Malas, who heads CHUM’s innovation center. “It was created over time. And clinicians not only used knowledge from the literature, they also developed it.»

Which is still happening: approximately 2000 new scientific articles are published each week. More than 100,000 COVID-related publications were indexed in 2020, nearly 5% of all scientific articles.

And it was to get through this sea of ​​information that CHUM turned to MIMs. Mainly composed of data scientists and bioinformaticians, the Get started De Montréal developed a solution based on artificial intelligence.

By using the scientific lexicon compiled by clinicians and library experts, it is possible to sort publications according to need. Furthermore, “we will be able to indicate how reliable you are with the information in the articles,” said Sarah Jenna, co-founder and CEO of MIMs.

“This will allow clinicians to improve their ability to do scientific monitoring,” said one holding a PhD in cell biology and microbiology.

My Smart Machinery

Made in 2016, MIMs are largely a Get started in artificial intelligence that develops and markets SaaS (Software-as-a-Service) software solutions for the pharmaceutical sector.

In addition to ensuring monitoring of scientific publications, MIM algorithms make it possible to collect and process impressive amounts of data on patients in the stages of development of a drug.

Useful data in the preclinical phase, says Sarah Jenna. “Even before developing a drug, our software allows companies to better understand what differentiates patients or subgroups of patients.»

By knowing “what differentiates one individual from another”, medications and biotechs can direct the formation of molecules according to the subgroups that are likely to respond to a treatment. Thus, companies reduce the likelihood of failing at drug approval stages by authorities, such as the Food and Drug Administration.

“The lack of drug effectiveness is associated with a failure rate of nearly 70% in stages 2 and 3,” he said, noting that it takes more or less 10 years to develop a drug. and the associated costs are expected to be approximately $ 1 billion.

“By dividing the failure rate into phases 2 and 3, for example, pharmaceutical companies can save up to $ 500 million,” he said.

COVID as a lever

The software is also used in the agricultural sector: animal health, nutrition and genetics. However, agricultural activities were hampered by the pandemic. This is not the case in the health sector, where COVID-19 has largely served as a driver for the development of new technologies.

The potential of MIMs has not gone under the radar of investors. The company raised five million dollars in a funding round that ended two weeks ago. This amount is in addition to the three million dollars collected in the previous two rounds, in 2017 and 2019. To investors, we point to Anges Québec, Desjardins Capital, Real Ventures, MEDTEQ and the StandUp Ventures of Ontario.

In December, MIM was named one of North America’s 100 Most Promising Technology Companies Red Herringa Silicon Valley technology publication.

To be seen in the video

Leave a Comment